Mural Oncology plc MURA 深 沪
已收盘 09-19 16:00:00 美东时间
2.08
0.000
0.00%
华盛通- 最 高2.08
- 今 开2.07
- 成交量 23.79万股
- 最 低 2.07
- 昨 收 2.08
- 总市值 3603.48万
- 52周最高 4.74
- 市盈率 静 --
- 换手率 1.37%
- 52周最低 0.95
- 委 比 0.70%
- 总股本 1732.44万
- 历史最高 17.00
- 量 比 1.56
- 振 幅 0.48%
- 历史最低 0.95
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mural Oncology shares are trading higher after the company announced it will be acquired by a Xoma Royalty subsidiary for between $2.035 and $2.24 cash per share.
Mural Oncology shares are trading higher after the company announced it will be...
08-21 01:38
Mural Oncology Plc Announces Acquisition Agreement
Mural Oncology Plc ( ($MURA) ) just unveiled an announcement. On August 20, 202...
08-20 21:18
Mural Oncology Q2 EPS $(2.78) Misses $(1.51) Estimate
Mural Oncology (NASDAQ:MURA) reported quarterly losses of $(2.78) per share which missed the analyst consensus estimate of $(1.51) by 84.11 percent. This is a 49.46 percent decrease over losses of $(1.86) per share from
08-04 20:19
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
Mural Oncology plc announced its second-quarter 2025 financial results and business update. The company discontinued clinical development of its lead product candidate, nemvaleukin alfa, and is exploring strategic alternatives to maximize shareholder value. Cash and cash equivalents were $77.1 million as of June 30, 2025, with an estimated $43 million to $48 million by December 31, 2025, if no strategic transaction is completed. The company incur...
08-04 12:00
MURANO GLOBAL Enhances Corporate Strategy To Build Bitcoin Treasury; Enters Into An Up To $500M Standby Equity Purchase Agreement With Yorkville
Murano to Enhance Existing Core-Strategy21 Bitcoin (BTC) Purchased to Date; Aims to Become a Major BTC HolderJoins BTC Inc & Michael Saylor's Strategy-Backed Initiative "Bitcoin for Corporations" as Chairman's Circle
07-07 20:09
期权扫描 | 利空突袭英伟达！期权成交量缩减至250万张；美国银行绩后看涨期权成交占比超64%
利空突袭英伟达！期权成交量缩减至250万张；美国银行绩后看涨期权成交占比超64%；Palantir隔夜大涨6%，但遭一PUT单押注看跌>>
04-16 15:32
美股大行评级 | 潜在涨幅706.45%！Guggenheim上调InflaRx目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1111936502896275457.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持InflaRx(IFRX)"买入"评级，目标价从7美元升至10美元</p> <p>• Oppenheimer：维持Corvus Pharma(CRVS)"跑赢大市"评级，目标价从14美元升至15美
03-27 09:48
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025.
03-25 21:28
Jones Trading Downgrades Mural Oncology to Hold
Jones Trading analyst Soumit Roy downgrades Mural Oncology (NASDAQ:MURA) from Buy to Hold.
03-25 20:32
Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial
Mural Oncology (NASDAQ:MURA), which was spun out of Irish biotech Alkermes (NASDAQ:ALKS) in 2023, lost ~47% in the premarket on Tuesday after the company announced plans to halt a Phase 3 trial for ne...
03-25 20:27
